European Inter-University Certificate in Clinical Hemostasis

Section 1

Title of the Certificate: European Inter-University Certificate in Clinical Hemostasis and Thrombosis

Universities Involved: University Claude Bernard Lyon I – France (Leading University delivering certificate)

Catholic University of Louvain - Belgium

University of Geneva – Switzerland

Humanitas University Milan - Italy

Medical University of Vienna – Austria

University of Amsterdam – The Netherlands

Project Summary: The University Certificate in Clinical Hemostasis and Thrombosis was created in 2007 in Lyon-France and was validated as a Continuous Medical Education (CME) program in 2018. The certificate was transformed into a European Inter-University Certificate in 2023 with the participation of the University of Lyon 1, Catholic University of Louvain, and the University of Geneva.

The collaborative inter-university initiative involving three universities has proven to be very successful, as evidenced by the positive feedback and satisfaction expressed by the candidates who took the course in 2023. This encouraging result has motivated us to extend our efforts to other European countries and to involve several internationally renowned experts in the process.

The objective of this European Inter-University Certificate in Clinical Hemostasis and Thrombosis is to train physicians who manage patients with bleeding disorders and/or thrombosis. The program includes the management of inherited bleeding disorders, acquired bleeding disorders, venous thromboembolism and arterial thrombosis. The goal is to provide general knowledge and skills to ensure the management of acute cases in emergency and also long-term follow-up and treatment for these rare hematologic disorders. The target audience includes specialized physicians and/or fellows in hematology, emergency medicine, internal medicine, anesthesiology, cardiology, vascular medicine, medical biology/pathology, pediatrics, and any other specialties involved in haemostasis and thrombosis.

This academic project, independent from pharmaceutical industry, also aims to promote the sub-discipline of Clinical Hemostasis at European level and to train young European physicians in the diagnosis and management of bleeding disorders and thromboses.

The European Inter-University Certificate in Clinical Hemostasis and Thrombosis has obtained the support and partnership of the European Rare Disease Network in Hematology "EuroBloodNet," which has agreed to support this unique educational program.

The educational program of the European Inter-University Certificate in Clinical Hemostasis and Thrombosis will be organized as follows:

- 91 hours of e-learning with recorded educational material: Each recorded educational lecture typically necessitates 2 to 3 hours of personal study for candidates to fully absorb the content.
- 25 hours of in-person workshops
- a one-week clinical preceptorship in a Clinical Hemostasis department (optional)
- a written knowledge assessment to validate this academic program

Attendance at 90% of the face-to-face workshops and a passing grade (50/100 points) on the written exam are required to receive the certificate.

Section 2 - Pedagogical Director and Instructors

European Inter-University Certificate in Clinical Hemostasis and Thrombosis is supported by the ERN EuroBloodNet

Director of the program : Professor DARGAUD Yesim

Specialization: Hematology – Haemostasis and Thrombosis

Phone : +33 4 72 11 88 22

E-mail : ydargaud@univ-lyon1.fr

Affiliated to: University of Lyon – Medical School of Lyon Est

Certificate Coordinator in France: DARGAUD Yesim

Certificate Coordinator in Belgium : HERMANS Cedric

Certificate Coordinator in Switzerland : FONTANA Pierre

Certificate Coordinator in Italy : MANCUSO Maria Elisa

Certificate Coordinator in Austria : AY Cihan

Certificate Coordinator in The Netherlands : FIJNVANDRAAT Karin

The Educational Committee, including medical coordinators of the program in each partner universities, will meet once a year in September to evaluate and update the program based on significant medical-scientific advances in the field and students' feedback.

Section 3 - Needs Assessment

Certain coagulation disorders, such as hemophilia, are rare and responsible for serious complications that are often poorly understood by non-specialized physicians. Inappropriate clinical management of the patients with rare bleeding disorders may have dramatic consequences for these patients. Conversely, venous thromboembolic disease and arterial thrombosis, are common and serious, responsible for significant morbidity and mortality. A better knowledge on these diseases and anticoagulant treatment may improve patient care.

This academic program will accept a maximum of 20 candidates per year. Since 2007, for the previous versions of this educational program, a waiting list of candidates wishing to attend the program was necessary because of a large number of candidates, clearly indicating a real need of physicians training in hemostasis and thrombosis. The transformation of this University Certificate into a European Inter-University Certificate is a real opportunity to attract young physicians issued different specializations to the field of Clinical Haemostasis and Thrombosis. Thus, this program will contribute to address the shortage of specialists in clinical haemostasis and thrombosis observed in many European countries. Due to the privileged partnership of the European Union with Switzerland, and the close medical exchanges with colleagues at the University Hospital of Geneva the participation of the University Hospital of Geneva in this European project is essential.

Section 4 - Educational objectives of the training

The European Inter-University Certificate in Clinical Hemostasis and Thrombosis addresses the educational needs in Clinical Haemostasis and Thrombosis. Its purpose is to train physicians to understand the specific aspects of hemostasis disorders and to derive appropriate practice.

Provide theoretical and practical medical and scientific knowledge necessary for the management of thromboses or bleeding disorders.

Acquire and master knowledge of antithrombotic and procoagulant treatments.

Provide hands-on training to better understand issues related to hemostatic disorders through interactive workshops.

Promote the development of multidisciplinary research in clinical hemostasis.

Section 5 - Duration of the Education

1 academic year

Section 6 - Program and Schedule of the Training

- Theoretical teaching (e-learning): 91 hours
- Practical clinical teaching (workshops): 25 hours
- Clinical preceptorship (optional): 1 week

Section 7 - Target audience :

Priority will be given to physicians holding a European medical degree or an equivalent foreign diploma authorizing them to practice medicine AND a specialty diploma in hematology, anesthesiology and intensive care, internal medicine, cardiology, vascular medicine, emergency medicine, medical biology/pathology.

European residents enrolled in a postgraduate specialization program of hematology, anesthesiology and intensive care, internal medicine, cardiology, vascular medicine, emergency medicine, or medical biology.

Candidate Selection Process: Candidates will be selected on the basis of their curriculum vitae and a letter of motivation addressed to the program coordinator of their country. If necessary, an interview with the coordinator will be organized. The approval of the program coordinator is mandatory for the registration to this academic program.

Each candidate will take a registration at the University Claude Bernard Lyon 1 (UCBL) and will receive from UCBL:

- the French inter-university diploma
- and a certificate of attendance and successful completion incorporating the logos of all partner universities

Minimum number of candidates/year (below which the program will not open): 10
Maximum number of candidates/year: 20

Method of communication with the candidates The University Lyon 1 website and via email with the program coordinators.

The educational materials will be made available each January on Université Lyon 1 (UCBL)'s MOODLE platform.

Enrolled students will have full access to all resources and can download them using their university credentials.

Section 8 - Pedagogical methods and tools used

Each topic is taught by an international expert with extensive experience in the field. The multidisciplinary nature of the candidates and the limited number of places allow for continuous interactivity and a highly valuable exchange between candidates and lecturers. The workshops, based on clinical cases and practical case scenarios, enable the development of clear approaches to dealing with typical situations and provide insights and tools necessary to deal with more complex clinical situations. Attendance to the workshops is MANDATORY.

Section 9 - Methods of evaluation of the educational program by participants

The teaching, the educational quality of the teaching material used, the content of the program, and the organization of the Certificate will be systematically evaluated by the candidates through a satisfaction survey.

Section 10 - Knowledge Assessment Methods

Attendance to workshops is mandatory and determines eligibility to take the written exam. The Program Director will monitor attendance of the candidates. A maximum of 1 day of absence will be tolerated for the total 6 days of workshops.

Assessment methods: Three 40-min exam sessions covering the entire program and consisting of 6 clinical cases (two on bleeding disorders, two on thrombotic disorders and two on antithrombotics) will be organized.

Conditions for obtaining the certificate: To validate and obtain the certificate, the candidates must score a minimum of 50/100 points on the average of the written exams.

Attendance for 90% of the training determines eligibility for the validation exam. A certificate of attendence with the logos of all participating universities and the signature of all coordinators will be provided to all candidates after the face-to-face workshops.

Participation to a clinical preceptorship is strongly recommended.

Exams : A written exam will be organized in June of each year in all participating universities. Each country coordinator is responsible for organizing the exam at his or her university. The questions will be identical in each country, and the exam will be organized on the same day and at the same time in all participating universities. The coordinators of the partner universities will organize the examinations in their department.

A second chance exam may be organized in October upon the decision of the educational committee, if there is a certified major reason (medical or others) that prevents the validation of an exam. The second chance exam may be granted and organized on a case-by-case basis, subject to the decision of the Education Committee and in accordance with the regulations of Claude Bernard University Lyon 1. It is not systematic.

Organization of exams for candidates from the overseas departments and territories or from a country where there is no partner university : It is possible to organize the exam by videoconference. The director of the program will be responsible for the organisation of the exam (to send a videoconference link, the exam questions with an attention to the simultaneous timing of the exam, and to collect the candidates answers).

Section 11 - Registration Fees

The registration fee, set by Claude Bernard University Lyon 1, will be the same for all candidates.

Section 12 - Declaration of Conflicts of Interest

This academic program strives to attain the highest standards of integrity. All speakers, trainers and presenters are asked to declare any conflicts of interest (COI) that they might have relating to their presentations.

Definition: A COI exists when professional judgement, for example concerning presentation or critical appraisal of research evidence or discussion about the most appropriate management of a clinical case, may be influenced by a secondary interest (such as financial gain).

Time Frame: Presenters must declare any relevant interests relating to the previous 36 months and the next 12 months from the date of their presentation.

All declarations must be submitted before January each year.

A declaration of competing interests form is available at the end of this document.

Section 13 - Declaration of Independence from the Pharmaceutical Industry

The European Inter-University Certificate in Clinical Hemostasis and Thrombosis is financially independent of the pharmaceutical industry. Any relationship must be disclosed and will be discussed.

Section 14 - Review

The content of the program and the workshops will be reviewed at least every 2 years from the date of its creation according to the attendees' feedback, the evolution of scientific and medical knowledge.

TEACHING PROGRAM

I- BLEEDING DISORDERS

I.1 General Hemostasis Module (E-Learning)

1- Physiology of primary hemostasis, coagulation and fibrinolysis (Y. Dargaud)

2- Routine hemostasis tests for clinicians (A. Bowyer)

I.2 Hemophilia module (E-Learning)

3- Overview of hemophilia, genetic basis, pathophysiology, clinical presentation, complications, diagnostic methods, interest in and methods of prenatal diagnosis, molecular abnormalities involved and principles of family screening (K. Fijnvandraat)

4- Management of bleeding events in hemophiliacs and extended half-life factors (ME Mancuso)

5- Hemophilic arthropathy and the place of ultrasound monitoring in hemophilia centers (M. DiMinno)

its orthopedic management ; pseudotumors (G. Pasta)

6- Management of surgery related bleeding risk in hemophiliacs with or without inhibitors (C.Hermans)

7- Mild and moderate hemophilia (diagnosis and management) (P. Chowdary)

8- Non-factor therapies for the treatment of hemophilia / FVIII mimetics (P. Lenting [biochemistry] and J Mahlangu [clinical data])

9- Non-factor therapies for the treatment of hemophilia / rebalancing therapies

Anti-TFPIs (V Jimenez Yuste)

Fitusiran (Y. Dargaud)

10- Management women with hemophilia and carrriers: diagnosis, management, pregnancy monitoring with instructions for obstetricians (R. d'Oiron)

11- Gene therapy for hemophilia (W. Miesbach)

12- Inhibitor Risk in patients with hemophilia and treatment of patients with inhibitors (S. Gouw)

13- Specificities of the management of hemophilia in the elderly (R. Schutgens)

14- Specificities of hemophilia management in pediatrics (K. Fijnvandraat)

15- Management of the surgery related thrombosis risk in patients with bleeding disorders (C. Hermans)

16- Therapeutic education for patients with hemophilia (Nanda Uitslager - NL)

17- Diagnosis and therapeutic management of acquired hemophilia (A. Tiede)

18- Laboratory assays for hemophilia, from diagnosis to therapeutic follow-up (incl.genetics) (A. Bowyer [phenotypic] and A. Pavlova [genetics])

I.3 von Willebrand module (E-Learning)

18- von Willebrand disease, genetic basis, pathophysiology, clinical presentation, complications, diagnosis methods (D. Lillicrap)

19- Management of bleeding risk during surgery in patients with von Willebrand disease: treatment and follow-up (M. Lavin)

20- Management of gastrointestinal bleeding in patients with von Willebrand disease (S Susen)

21- Management of bleeding risk during pregnancy in patients with von Willebrand factor deficiency (van Galen KPM)

22- Acquired von Willebrand Factor Deficiency (Frank Leebeek)

23- Laboratory assays for VWD (incl.genetics) (J. Eikenboom)

I.4 Rare Coagulation Deficiencies Module (E-Learning)

24- Rare coagulation factor deficiencies FII, FVII, FX, FV, FXI, FXIII (S. Schols)

25- Fibrinogen abnormalities (A. Casini)

26 - Vascular Differential Diagnosis: I - Collagen Abnormalities (*Fransiska Malfait 1, Sofie Symoens 1, Delfien Syx BELGIUM ????*)

27 - Vascular Differential Diagnosis: II- Rendu Osler disease (P. Edery)

I.5. Hyperconsumption and hepatic insufficiency module (E-Learning)

28- Liver failure, assessment of bleeding risk and therapeutic management in the surgical context (P. Chowdary and T. Lisman)

29- Coagulopathy in polytrauma patients (C. Sandroni)

30- ADAMTS 13 and thrombotic microangiopathy (A. Veyradier)

31- DIC (Cheng-Hock Toh)

I.6. Platelets module (E-Learning)

32- Inherited platelet disorders (Paolo Gresele)

33- Immunologic thrombocytopenic purpura (ITP) (*A Janssens Belgium*)

34- Diagnosis and therapeutic management of inherited thrombopathies (M. Fiore)

35- Diagnosis and management of inherited thrombocytopenia (CL Balduini)

36- Management of thrombocytopenia during pregnancy (R. Kadir)

37- Platelet transfusions: characteristics of concentrates, indications, monitoring (a blood banker?)

38- Perioperative management of antiplatelet therapies (P. Fontana)

II- FACE-TO-FACE WORKSHOP ON BLEEDING DISORDERS IN LYON

Assessment of bleeding risk before surgery (F. Bonhomme and Y. Dargaud)

Management of hemophilia with and without inhibitors (ME Mancuso and C Hermans)

Hemophilia and surgery: How to organize elective surgery in patients with hemophilia, multidisciplinary approach, target FVIII and IX levels for different types of surgery, postoperative rehabilitation. (ME Mancuso and Y. Dargaud)

Management of Hemophilia at extreme ages - pediatrics and geriatrics (K. Fijnvandraat and C. Hermans)

Women with hemophilia and management of pregnancy in symptomatic and asymptomatic carriers (R. d'Oiron)

Clinical cases on von Willebrand disease (K. Fijnvandraat and Giancarlo Castaman)

- types 1, 2 and 3 and acquired
- prophylaxis in patients with VWD
- characteristics of different Willebrand factor concentrates
- Use of DDAVP

Rare inherited deficiencies (A. Casini and Y. Dargaud)

Clinical cases on inherited and acquired platelet disorders (M. Fiore)

DIC, LIC and liver failure (JS David)

Anticoagulants induced bleeding (P. Fontana)

III-THROMBOTIC PATHOLOGIES

III.1 Thrombophilia module (E-learning)

1- Thrombophilia markers (P. Morange)

III.2 Venous Thrombosis Module (E-learning)

2- DVT diagnosis strategies (M. Righini)
3- Pulmonary embolism diagnosis strategies (M. Righini)
4- Treatment of acute VTE (C. Ay)
5- Optimal duration of anticoagulation in VTE (F. Couturaud)

6- Follow-up after DVT or PE: post-thrombotic syndrome and post-embolic pulmonary hypertension (L. Bertoletti)

7- Vena cava filters in VTE (Michael J Lee)

8- Prevention of VTE in surgery and medicine (C. Ay)

9- Antiphospholipid syndrome and catastrophic APL syndrome (S. Zuily)

10- Management of venous thrombosis of unusual localisations (cerebral venous thrombosis, abdominal veins, ovarian veins, ophtalmic veins…) (W. Ageno)

11- Venous Thrombosis of the Upper Limbs (G. Poenou)

12- Management of Superficial Venous Thrombosis (Arina J. ten Cate-Hoek)

13- The Role of Interventional Radiology in VTE and Post-Thrombotic Syndrome (G. Pernod)

14- Vascular Surgery in VTE *(M De Perrot)*

15- Treatment Strategies in Chronic Thromboembolic Pulmonary Hypertension (L. Bertoletti)

III**.3. Anticoagulant therapy and its Complications Module** (E-learning)

16- Direct anti-Xa molecules (G. Jourdi)

17- Direct Antithrombin molecules (G. Jourdi)

18- Prescription, monitoring of heparin and its derivatives. Management of heparin overdose (J. Douxfils)

19- Heparin-Induced Thrombocytopenia (C. Pouplard)

20- Use of Heparins in Dialysis Patients with Renal Insufficiency (Oliver Königsbrügge)

22- Vitamin K antagonists and reversal of VKA (G. Poenou)

23- Management of anticoagulants in the perioperative period (P. Fontana)

24- Future anticoagulant treatments (anti-XIa and others) (G. Jourdi)

III.4. Thrombosis and Special Populations Module (E-learning)

25- Thrombosis and Cancer (C. Ay)

26- Pregnancy and VTE (S. Middledorp)

27- Hormone therapy and thrombosis risk (J. Douxfils)

28- The role of hematologist in the management of Fetal Losses/Obstetrical Complications (IUGR/Preeclampsia..) and Vascular-Placental Abnormalities (Marc Rodger)

29- In vitro fertilization and thrombosis risk *(Pelle Lindqvist)*

30- VTE in pediatrics and anticoagulant prescription in pediatrics (C. Male)

31- Venous malformations *(Scully M, London)*

III.5. Arterial Thrombosis Module (E-learning)

32- Pathophysiology of arterial thrombosis and atherosclerosis *(CHRISTOPHE BEAULOYE – Bruxelles)*

33- Strokes and Transient Ischemic Attacks - Management in Stroke Centers (L. Mechtouff)

34- Antithrombotic Management of Acute Coronary Syndromes (Riouffol G)

35- Role of Platelet Function Tests in Antiplatelet Prescribing Strategy (P. Fontana)

36- DOACs in arterial thrombosis? (W. Ageno)

IV- WORKSHOPS ON THROMBOSIS AND ANTICOAGULANTS

Thrombophilia: Who should be screened for thrombophilia and when? Should familial thrombophilia screening be performed? (Yesim Dargaud, Geraldine Poenou)

Venous thromboembolic disease: Duration of Treatment and Choice of Anticoagulant (Laurent Bertoletti)

DOACs in frail patients - clinical cases in obese, renally impaired and geriatric patients (Laurent Bertoletti)

Thrombosis and cancer (C. Ay and an oncologist from Lyon)

Anticoagulant Complications (Bleeding and Heparin-Induced Thrombocytopenia) (C. Ay and C. Pouplard)

Prevention of thrombotic risk in pregnant women (Yesim Dargaud)

AGREEMENT BETWEEN UNIVERSITY CLAUDE BERNARD LYON 1 (Leading University), PARTNER UNIVERSITIES and EUROBLOODNET RELATING TO THE EUROPEAN INTER-UNIVERSITY DIPLOMA IN CLINICAL HEMOSTASIS

Example

BETWEEN

CLAUDE BERNARD LYON 1 UNIVERSITY (UCBL) (Leading University)

Located...

Represented by

AND

CATHOLIC UNIVERSITY OF LOUVAIN (Belgium)

Located

Represented by

AND

UNIVERSITY OF GENEVA (Switzerland)

Located

Represented by

AND

HUMANITAS UIVERSITY OF MILAN (Italy)

Located

Represented by

AND

MEDICAL UNIVERSITY OF VIENNA (Austria)

Located

Represented by

AND

UNIVERSIT OF AMSTERDAM (The Netherlands)

Located

Represented by

AND

EUROBLOODNET ERN

Located

Represented by

It is agreed:

ARTICLE 1: PURPOSE OF THE AGREEMENT

All registrations will be centralized at the Claude Bernard University Lyon 1. All partner universities will actively contribute to teaching through the involvement of their faculty members. Registering at a single university will allow for budget centralization and facilitate the management of expenses related to teaching, primarily represented by covering the travel costs of experts participating in the MasterClasses. Thus, regardless of the number of registrants in each country, all faculty members required to travel to lead the MasterClasses will be easily reimbursed by Claude Bernard University Lyon 1.

The official language of the program will be English. EuroBloodNet is an integral part of this European Inter-University Certificate and support the project. The support of EuroBloodNet will be necessary to provide a multilingual translator during the MasterClasses, who can assist certain participants in discussing and interacting more easily with the experts. EuroBloodNet can also support candidates who wish to benefit from mentorship in expert centers specializing in rare hemorrhagic and thrombotic disorders.

Each partner university will serve as an examination center in order to avoid additional travel costs for candidates. The coordinators of the partner universities will organize the examinations in their department.

ARTICLE 2 RIGHTS AND OBLIGATIONS OF THE PARTNERS

1- University of Lyon will be the sole institution responsible for managing all administrative aspects and centralizing the budget. There will be no expenditures, administrative tasks, or budgeting at the other partner universities.
University Claude Bernard Lyon 1 (UCBL) undertakes to cover the travel expenses of teaching staff.

2- The coordinators of each partner university commit to organizing examination sessions in June under comparable conditions across all institutions for the candidates of their country. They also agree to the terms governing the organization of examinations, and accept the possibility of examinations being conducted via videoconference. The responsibility for establishing the modalities of videoconference-based examinations lies with the Program Director at the University Claude Bernard Lyon 1 (UCBL).
3- Teaching staff agree to deliver their courses on a voluntary basis and without financial compensation.
4- EuroBloodNet commits to providing logistical and technical support to ensure the proper functioning of the program.
5- University Claude Bernard Lyon 1 (UCBL) commits to offering translation assistance for workshops, subject to the availability of dedicated funds.
6- Data protection: All partners undertake to comply with applicable data protection regulations in the handling of personal and institutional data related to the program.
7- Use of logos: The use of logos of University Claude Bernard Lyon 1 (UCBL), partner universities, and EuroBloodNet shall be subject to prior approval and must comply with the respective branding guidelines of each institution.

ARTICLE 3: CERTIFICATE OF ATTENDANCE AND SUCCESSFUL COMPLETION

The institutions undertake to have the attached "Certificate of Attendance and Successful Completion" validated by their statutory boards. Any modifications will be the subject of an amendment to this agreement. *(The certificate will feature the logos of all partner universities and will be designed collaboratively; a proposal will be shared shortly. All participants will receive both the certificate of attendance and successful completion (as described above) and the official French university diploma, as they will be registered at a French institution. Please note that the university diploma is the only document officially recognized by the French authorities.).*

Each candidate registered at the University Claude Bernard Lyon 1 (UCBL) and will receive from UCBL:

- the French inter-university diploma

- and a certificate of attendance and successful completion incorporating the logos of all partner universities

ARTICLE 3: PROCEDURE FOR WITHDRAWAL FROM AN INSTITUTION

Any possible withdrawal and its reasons will be discussed within the Educational Committee of the European Inter-University Certificate in Clinical Hemostasis. If no solution can be found for the reasons mentioned above, withdrawal will be possible after the end of the academic year, once the teaching and validation examinations for the current year have been completed.

ARTICLE 4: FINANCIAL CONDITIONS (in the case of transfers between institutions, a financial annex must be provided)

Experts participating to this academic program are volunteers. Faculty members will not be paid for the courses they teach, but their travel expenses will be reimbursed according to the usual local procedures of each partner university. **Lyon Claude Bernard university will cover the travel expenses of all lecturers.**

A translation assistance for French, Italian and German speaker attendees will be offered during the workshops thanks to a unrestricted educational grant from industry that will be donated to EuroBloodNet. NovoNordisk, Roche, CSL have already agreed to participate.

ARTICLE 5: REVIEW AND REVISION OF THE EUROPEAN INTER-UNIVERSITY CERTIFICATE IN CLINICAL HEMOSTASIS AND THROMBOSIS

The European Inter-University Certificate in Clinical Hemostasis and Thrombosis will be reviewed and revised every two years.

COI Statement

Full Name:

In relation to this presentation, I declare that I have received the following from a company that may be perceived to win or lose from the content of my presentation:

Funds for a member of staff

□ Yes □ No

Funds for research

□ Yes □ No

Fees for consultancy

□ Yes □ No

Fee for speaking at a symposium

□ Yes □ No

Sponsorship for attending a meeting

□ Yes □ No

I have been employed by an organisation that may be perceived to win or lose from the content of my presentation

□ Yes □ No

I hold stocks or shares in an organisation that may be perceived to win or lose from the content of my presentation

□ Yes □ No

I have other competing interests

□ Yes □ No

If yes, please specify:

My partner or other close family member has competing interests

□ Yes □ No